“Functional analyses of FBXW7 mutations in serous endometrial cancer”

Wednesday, October 23, 2019
12:00 – 1:00 pm

Michigan State University
Grand Rapids Research Center
Room 1102

Join via Zoom:
https://msu.zoom.us/j/355119510

Daphne W. Bell, PhD

Dr. Bell is a senior investigator at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health. She received her B.Sc. (Honors) in Zoology and Genetics and her Ph.D. in Biology and Biochemistry from The Queen's University of Belfast in Northern Ireland. She conducted her postdoctoral training at Fox Chase Cancer Center, Philadelphia, before joining Harvard Medical School and Massachusetts General Hospital, where she was an instructor of medicine from 1997-2004 and an assistant professor of medicine from 2004-2006. Dr. Bell's graduate and postdoctoral studies focused on the fine-mapping of genomic deletions in ovarian cancer and in malignant mesothelioma as a means to home in on regions of the genome containing putative tumor suppressor genes. While at Massachusetts General Hospital/Harvard Medical School, Dr. Bell and her colleagues made a number of seminal discoveries including the landmark discovery that mutations in the EGFR gene explain the dramatic clinical responses of non-small cell lung cancer patients to gefitinib, a small molecule inhibitor of EGFR. Her ongoing research aims to identify genomic alterations that drive clinically aggressive endometrial tumors, and to understand their functional consequences.